Boothbay Fund Management LLC Sells 201,674 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Boothbay Fund Management LLC reduced its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 52.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 181,042 shares of the company's stock after selling 201,674 shares during the quarter. Boothbay Fund Management LLC owned approximately 0.30% of Pyxis Oncology worth $282,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PYXS. Commonwealth Equity Services LLC raised its holdings in Pyxis Oncology by 61.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after purchasing an additional 10,000 shares in the last quarter. Sei Investments Co. bought a new position in shares of Pyxis Oncology in the 4th quarter worth about $95,000. Barclays PLC lifted its position in Pyxis Oncology by 20.2% during the 4th quarter. Barclays PLC now owns 77,013 shares of the company's stock valued at $121,000 after acquiring an additional 12,924 shares during the period. Dimensional Fund Advisors LP boosted its stake in Pyxis Oncology by 35.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 111,051 shares of the company's stock worth $173,000 after acquiring an additional 29,105 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Pyxis Oncology by 40.8% during the third quarter. Jane Street Group LLC now owns 49,558 shares of the company's stock valued at $182,000 after purchasing an additional 14,349 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PYXS. Royal Bank of Canada reissued an "outperform" rating and issued a $8.00 price target on shares of Pyxis Oncology in a research report on Wednesday, March 19th. HC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Pyxis Oncology in a research note on Wednesday, March 19th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $9.20.

Pyxis Oncology Price Performance

NASDAQ PYXS traded down $0.12 during mid-day trading on Tuesday, reaching $1.07. The stock had a trading volume of 491,944 shares, compared to its average volume of 736,297. The company has a fifty day moving average price of $1.05 and a 200 day moving average price of $1.78. Pyxis Oncology, Inc. has a 1 year low of $0.83 and a 1 year high of $5.39. The stock has a market cap of $66.28 million, a PE ratio of -1.04 and a beta of 1.15.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.01. The company had revenue of $16.15 million during the quarter. As a group, equities research analysts expect that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.